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Summary We recently defined a new early prognostic factor, the ER+(R) status, which permits the discrim-
ination of a group presenting a high risk of early relapse among the ER' patients. This group was referred to
as ER+(R2) in contrast to ER+(R1) which corresponded to the group of ER' patients having a lower risk of
early relapse. Taking into account the whole population including the ER- and inflammatory tumours, we
have extended this view and showed that ER+(R) status is a significant predictor of disease-free survival.
Determination of c-erbB-2 mRNA levels in the same series of tumours showed that high expression of
c-erbB-2 mRNA is significantly correlated with ER-, inflammatory tumours and with lymph nodes involve-
ment. Moreover, a multivariate analysis showed that c-erbB-2 mRNA overexpression was a significant
predictor of early relapse (P=0.02), as significant as ER negativity and ER+(R2). For ER' patients a high
level of c-erbB-2 mRNA constitutes a higher risk of relapse for both ER+(RI) and ER+(R2) patients.
However, in the case of ER- patients, early relapses were strongly correlated with c-erbB-2 overexpression.
The counterpart of this observation is that ER- patients with no overexpression of c-erbB-2 constitute a group
with a relatively good prognosis.
Management of breast cancer treatment depends on a good
knowledge of the prognostic factors enabling the identi-
fication of patients with either a low or high risk of recur-
rence. A knowledge of the steroid receptor status, specifically
the oestrogen receptor (ER), should allow the prediction of
the response to hormonal therapy and to some extent
disease-free survival, site of relapse and overall survival
(Knight et al., 1977; Pichon et al., 1980; Clark et al., 1983;
Allegra et al., 1979; Blanco et al., 1984; Fisher et al., 1983;
Hahnel et al., 1979; Saez et al., 1983). Although there is a
general agreement on the higher risk of relapse for receptor-
negative (ER-) patients, the prognostic value of ER status is
not accepted by all authors (Aamdal et al., 1984; Howell et
al., 1984; Felman et al., 1986; Parl et al., 1984). Among
ER-positive (ER') patients regarded as having a more
favourable prognosis, we have recently defined a group pre-
senting a high risk of relapse (May et al., 1989). This group
of patients, called ER+(R2), has been characterised by a
ratio of (ER-protein in fmol per mg total proteins) to (ER-
mRNA in pg per 4pg total RNA) higher than 1.5. Accord-
ing to these results, ER+(R) status has been assigned as an
early prognostic factor.
On the other hand, amplification of the c-erbB-2 gene is an
alteration frequently associated with breast cancer. This gene
encodes a transmembrane protein that shows extensive
homology with the receptor for epidermal growth factor
(Coussens et al., 1985; Bargmann et al., 1986; Yamamoto et
al., 1986), indicating that c-erbB-2 is a membrane-bound
receptor. A ligand for c-erbB-2, however, has not yet been
identified. A number of studies regarding amplification of
this gene in primary human breast cancer has been published
(see Table I for references). Depending on the authors, in-
cidence of amplification varies from 10 to 40%. Ampli-
fication of c-erbB-2 receptor gene in human breast cancer
was associated with high levels of both mRNA and protein
(see Table I for references). However, overexpression of the
c-erbB-2 gene depends not only on gene amplification, since
elevated levels of the c-erbB-2 receptor and c-erbB-2 specific
mRNA were observed in tumours containing a single copy of
the oncogene (Lacicix et al., 1989; Berger et al., 1988; Guerin
et al., 1989; Venter et al., 1987).
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The association between amplification of the c-erbB-2 gene
and poor prognosis in human breast cancer was first reported
by Slamon et al. (1987). Since then, contradictory results
concerning the associations between c-erbB-2 amplification,
clinicopathological features and risk of relapse have been
reported (see Table 1). It is interesting to note that significant
associations between c-erbB-2 amplification and positive
nodal status as well as the worst histological grade and
increase in relapse are observed more often in the groups of
patients having a higher incidence of amplification and/or
overexpression. In fact, recent results of Slamon et al. (1989),
Wright et al. (1989) and Tandon et al. (1989) obtained with
large populations of patients strongly support the assumption
that c-erbB-2 gene amplification and/or overexpression are
reliable guides to the prognosis of breast cancer.
The present study was performed in an attempt to cor-
relate the prognostic significance of ER+(R) status with the
c-erbB-2 prognostic factor. As direct measurement of c-erbB-
2 gene expression may be more relevant to disease (Tandon
et al., 1989), we have assessed the level of c-erbB-2 specific
mRNA in the series of breast cancers previously analysed for
the expression of ER-specific mRNA (May et al., 1989).
Results showed that ER+(R) status and c-erbB-2 mRNA are
two significant independent predictors of early relapse.
Materials and methods
Patients
Samples of untreated and non-metastatic breast carcinomas
were obtained by biopsy or tumorectomy from 89 patients
treated at 'Institut Gustave-Roussy' (Villejuif, France).
Seventy-six patients had an operable tumour. Depending on
the tumour size, either mastectomy or conservative treatment
was performed. In case of axillary nodes invasion, adjuvant
treatment was prescribed: taximofen for post-menopausal
women, chemotherapy for premenopausal women with loco-
regional radiotherapy for both groups of patients. The
remaining 13 patients had an inflammatory non-metastatic
tumour. This diagnosis was made on the basis of clinical
symptoms (oedema, hotness, redness in more than one-third
of the breast) and confirmed by biopsy. These patients were
treated by association of chemo-, radio- and hormono-
therapy. No surgery was performed.
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Table I Results obtained bydifferent groupsconcerning theassociation betweenc-erbB-2amplification or
overexpression and disease parameters
Amplif. or P valuesfor thedifferentfactors
overexpr. ER Histological Node
Authors n (%) status grade status IBC' DFS6
Amplification
Ali et al. (1988) 122 10 NS NS NS
Zhou et al. (l89) 157 11 NS NS NS
Van de Vijver et al. (1987) 95 17 NS NS NS
Zeillinger et al. (1989) 291 18 0.02
Lacroix et al. (1989) 57 19 NS 0.095 NS 0.046
Varley et al. (1987) 37 19 NS NS NS 0.0002
Guerinetal (1988) 115 20 <10-3 NS <0.02
Berger et al. (1988) 51 25 0.01 0.0002d 0.18
Gu&rin et al. (1989) 221 27 0.01 <0.001
Slamon et al. (1987) 86e 40 0.05 0.06 < 10-4
(1989) 345' 27 0.01
Over-expression'
Barnes et al. (1988) 195 9 NS 0.04f NS NS
Van de Vijver et al. (1988) 1899 14' 0.186 0.101 NS
Wright et al. (1989) 185 17h 0.028 0.035 NS 0.005
Tandon et al. (1989) 350' 17 0.02 0.0014
Lacroix et at. (1989) 53 26* NS NS NS 0.050
Berger et al. (1988) 51 40* 0.02d 0.02
Guerin et al. (1989) 201 47* <0.001i 0.05 0.002
NS, not significant. a'nflammatory breast carcinoma. bDisease.free survival. cOverexpression was
measuredateithertheprotein' ortranscription level . Parameteranalysed wasthenucleargrade.ePatients
with positive nodes. fCorrelation observed for infiltrating ductal tumours. 9Cinical stage II breast cancer.
hPer cent of patients with a strong membrane staining. 'Correlation observed for patients with positive
nodes.
Tissue samples
After histological verification, the samples selected by the
pathologist were carefully dissected, frozen and stored in
liquid nitrogen until required. Stroma cell contamination was
estimated for each sample. The levels of contamination were
scored by eye from ' + ' for less than 10% to ' + + + ' for a
concentration of more than 50% of stroma cells. High
stroma cell concentration was detected in only 11 tumours
and distributed over the different groups of patients.
Chemicals
3H-oestradiol (3H-E2) (100 Ci mmol-') was obtained from
the CEA (Commissariat i l'Energie Atomique, France). All
other reagents were of the highest grade available.
ER assay
ER levels were determined by the one-dose saturation
method (5 nM) using 3H-E2 as previously described (Martin
et al., 1981). The total amount of receptor was measured
after extraction with a buffer containing 0.4 M KCI. Tumours
with an ER level higher than 10 fmol mg-' of total protein
were considered as positive.
RNA extraction
Total cellular RNA was isolated from 0.3 to 0.5 g of frozen
tumour by the guanidium-caesium chloride method (Glisin et
al., 1974). Yields were quantified by spectrophotometry. The
quality of RNA was controlled by monitoring the integrity of
the 28 S and 18 S ribosomal bands following agarose gel
electrophoresis.
Northern blot analysis
Total RNA (4;Lg) was analysed by Northern blot as pre-
viously described (May et al., 1989). Rehybridisation of
filters was performed after treating Hybond N membrane
(Amersham) for 1 h in Tris-HCI 0.005 M, EDTA 0.002 M,
Denhart (pH 8) at 65C. RNA concentrations were deter-
mined by quantitative densitometric scanning of appropri-
ately exposed autoradiograms. Quantification was performed
by running in parallel known amounts of a single-stranded
recombinant DNA containing the insert used as probe. Each
sample was analysed at least twice and results were nor-
malised relative to the steady state level of P-actin mRNA.
Two aliquots of RNA extracted from the tumour of patient
no. 60 were run on every gel and used as reference for
comparison purposes.
The following DNA or plasmid probes were used in this
study after 32P-labelling by the 'random primed' DNA label-
ling method (Boehringer Kit, Mannheim); the 1200-bp Accl/
BamHI fragment of pMAC1 17 (ATCC collection) specific to
the c-erbB-2 mRNA and chicken-specific f-actin (May et al.,
1989).
Statistical methods
Survival times were measured from the date of diagnosis and
the multiple regression model developed by Cox (1972) for
censored survival data was used. This both allows the con-
sideration of several variables simultaneously and the identi-
fication of the variables which have an important effect on
disease recurrence and survival. Disease-free survival (DFS)
curves were obtained by the product limit method of Kaplan
and Meier (1958). Comparisons of DFS curves were based
on the log rank test and all other comparisons were made
using the x2 test.
Results
c-erbB-2 mRNA expression and correlation with other
prognosticfactors
We have previously quantified the ER-binding activities and
the steady-state levels of ER-mRNA for untreated, primary
breast carcinomas (May et al., 1989). In the current study, we
performed a quantitative analysis of steady-state levels of
c-erbB-2 mRNA on the same RNA preparations except for
one additional ER- carcinoma.
Figure 1 shows a representative Northern mRNA blot
obtained from 13 different tumours. A 4.8 kb mRNA species
was detected in positive samples. Quantification of c-erbB-2
mRNA was performed as described in Materials and methods432 E. MAY et al.
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Figure 1 Northern blot analysis of total RNA from 13 different
primary breast tumours. 4 pg of total RNA were electrophoresed
and hybridised with a c-erbB-2 cDNA probe. After autoradio-
graphy (4 days without an intensifying screen), blots were dehy-
bridised and then hybridised with a P-actin-specific probe. The
two resulting autoradiograms are superimposed. Numbering of
the patients is identical to that in the previous paper (May et al.,
1989). Patient no. 60 was used as reference.
and expressed in pg per 4 pLg of total RNA. c-erbB-2 mRNA
amounts displayed a wide range of values from less than 5 pg
to as much as 190 pg. Under our experimental conditions,
the level of c-erbB-2 transcripts in the MCF-7 cell line corre-
sponded to less than 5 pg per 4 Lg of total RNA. This is
likely to reflect the normal level of expression. The MCF-7
cells show similar expression to that of normal mammary
epithelial cells and fibroblasts (Kraus et al., 1987). Fifty-
seven per cent of the population correspond in fact to this
c-erbB-2 mRNA level (Figure 2). The remaining patients
were divided into four equal groups corresponding to 5-10,
10-20, 20-50 and 50-190 pg of specific mRNA per 4pg of
total RNA, respectively (Figure 2). These groups were
analysed to establish the cut-off value of c-erbB-2 mRNA
that would best distinguish patients at high risk of relapse. A
cut-off value of 20 turned out to provide a significant separa-
tion. Our population of 89 patients was then separated into
three categories corresponding to normal (less than 5 pg),
moderate (5-20 pg) and high (20-190 pg) level expression.
High levels of c-erbB-2 mRNA were detected in 23% (20/89)
of tumours (Table II).
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Figure 2 c-erbB-2 specific mRNA levels in 89 primary human
breast cancer. Specific mRNA levels were de'ermined as described
in Materials and methods.
Correlations between clinico-pathological data and the
level of c-erbB-2 mRNA expression are presented in Table II.
We have included the ER+(R) status according to previously
published results (May et al., 1989). This parameter, esti-
mated for ER' tumours, was defined by the ratio ER-protein
(expressed in fmol mg-') to ER-mRNA (expressed in pg per
4 pg of total RNA). Groups ER+(RI) and ER+(R2) corre-
spond to tumours having a ratio lower and higher than 1.5,
respectively.
Results presented in Table II showed that high levels of
c-erbB-2 mRNA were significantly correlated with (i) inflam-
matory carcinoma (P = 0.007), (ii) presence of involved
lymph nodes (P = 0.03) and (iii) ER negativity (P = 0.02).
There was no significant correlation between c-erbB-2 mRNA
levels and age of the patient at diagnosis, histological grade
or ER+(R) status.
Table II c-erbB-2 transcription in relation to the clinicopathological and biological
characteristics of 89 patients with breast cancer
Number ofpatients
c-erb-2 mRNA expression' p
Parameters Classes Normal Moderate High Total values
Total 51 18 20 (23%) 89
Age at diagnosis (years) <40 6 1 4 11
40-60 25 5 10 40 NS
>60 20 12 6 38
Clinical tumour type NBCb 45 (59%) 18 (24%) 13 (17%) 76 0.007
IBCb 6 (46%) 0 (0%) 7 (54%) 13
Histological gradec 1 3 2 0 5
II 30 9 11 50 NS
III 17 7 8 32
Lymph-nodes statusd N- 22 (63%) 11 (31%) 2 (6%) 35 0.03
N+ 23 (56%) 7 (17%) 11 (27%) 41
ER status ER-c 10 (48%) 2 (9%) 9 (43%) 21 0.02
ER+e 41 (60%) 16 (23%) 11 (16%) 68
ER+(R) statusf ER+(R1) 25 (62%) 8 (20%) 7 (18%) 40 NS
ER+(R2) 16 (57%) 8 (29%) 4 (14%) 28
aExpressed in pg per 4pg of total RNA. Depending on the level ofc-erbB-2 mRNA,
patientsweredividedintothreecategoriescorrespondingrespectively tonormal (<5 pg),
moderate (5-20pg) and high (>20 pg) expression of c-erbB-2 mRNA. bNBC, non-
inflammatory breast cancer; IBC, inflammatory breast cancer. cAccording to the
definitionofBloom and Richardson(1957), histologicalgrading was notavailable for two
cases. dParameteravailableonlyfornon-inflammatory operable tumours(76cases). 'ER-
and ER+ correspond to tumours with less and more than 10 fmol ER per mg protein,
respectively. fER+(R) status was determined for ER+ patients by calculating the ratio
ER-protein(infmol permgoftotalprotein) to ER- mRNA(inpgper4pgoftotalARN).
ER+(RI) patients with a ratio < 1.5, ER+(R2) patients with a ratio > 1.5 (May et al.,
1989).
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Prognostic significance ofc-erbB-2 mRNA andER-/ER+ (R)
status as compared to classicalprognosticfactors
Univariate and multivariate analysis was performed to cor-
relate all available prognostic factors including c-erbB-2
mRNA and ER+(R) status with disease-free survival data.
Results are presented in Table III. It is important to point
out that we selected for patients exhibiting a primary tumour
not yet treated either by chemo-, radio- or hormono-therapy.
The median follow-up available for this analysis was 30
months. Univariate as well as multivariate analysis showed
that neither age at diagnosis nor histological grade were
significant in predicting disease outcome. For populations
reduced to operable tumours (76 patients), lymph-node
involvement was also not significant. The relatively small size
of our population as well as the short median follow-up
available could account for this observation (Contesso et al.,
1975).
In agreement with previously published data (Lacroix et
al., 1989; Guerin et al., 1989), univariate survival analysis
showed that patients with inflammatory carcinoma had a
very poor prognosis (P< 10-4). However, this parameter
loses its significance on multivariate analysis including age,
histological grade, ER-/ER+(R) status and c-erbB-2 mRNA.
This indicates that the clinical tumour type as a prognostic
factor was dependent on the other significant prognostic
factors.
c-erbB-2 mRNA overexpression was as significant as
inflammatory tumours on univariate analysis. Moreover,
high levels of c-erbB-2 mRNA (>20 pg per 4iLg of total
RNA) was still highly significant on multivariate analysis in
predicting relapse in the relative short-term (P<0.02). The
group of patients with normal levels of c-erbB-2 mRNA
(< 5 pg) was taken as reference in this analysis. It is interest-
ing to note that patients with moderate overexpression
(5-20 pg) had the same low-risk of relapse as patients with
normal levels of c-erbB-2 mRNA.
On the other hand, both ER- and ER+(R) status were
highly significant in predicting disease outcome on univariate
as well as on multivariate analysis. These analyses (Table III)
were performed by grouping the 89 tumours into three
groups corresponding to ER-, ER+(RI) and ER+(R2)
tumours, the ER+(RI) group being reference for multivariate
analysis. Both ER- and ER+(R2) patients had a high risk of
early relapse (P=0.01). The risk of relapse for ER+(R2)
patients is comparable to that of patients which have an
overexpressed c-erbB-2 gene. Our first identification of
ER+(R2) as a predictor of early relapse was performed on a
population confined to ER' patients having a non-inflamma-
tory tumour. Results presented here, extend our previous
conclusion to the whole population, including ER- and
inflammatory tumours.
Table III Comparison of the different factors for predicting disease-
free survival
Univariatea Multivariate analysis"
Parameters P-values Classes RR" P-values
Age at diagnosis NS NS
Histological grade NS NS
Node status NS NS
Clinical tumour type <10-4 NBCd
IBCd 0.15
c-erbB-2 mRNA < 10-4 normal
expressione moderate 0.8 NS
high 4.9 0.02
ER-/ER+(R) 0.001 ER-' 5.2 0.01
statusf ER+(Rl)g
V
ER+(R2)' 5.0 0.01
NS, not significant. 'Classes taken as reference for analysis using the
Cox regression model. aUnivariate anlaysis was performed by using the
log rank test. bMultivariate analysis was performed by using the Cox
regression model. cRelative risk. d.As defined in legend to Table II.
fPatients were divided into three classes according to ER-/ER+(R)
status. 'ER-, ER+(RI) and ER+(R2) classes have been defined in the
legend to Table II.
Finally, a log rank test with DFS data was performed in
order to evaluate the relative risk of relapse of patients with
two poor prognostic factors, c-erbB-2 overexpressing and
ER- or ER+(R2). According to our previous observation
showing that patients with normal and moderate levels of
c-erbB-2 mRNA had in fact the same low risk of relapse,
these two groups were mixed for the present analysis. Results
are presented in Table IV and Figures 3 and 4. Twenty-two
relapses were observed. Most of them (18/22) were distal
metastasis. The four remaining consisted of three local
relapse and one controlateral cancers.
Figure 3 shows the disease-free interval for ER' patients.
The ER+(R2) group was at a higher risk of relapse than the
ER+(R1) group for patients having normal or moderate level
of c-erbB-2 mRNA as well as for those overexpressing
c-erbB-2 mRNA. Moreover, high level of c-erbB-2 mRNA
constituted an additional risk of relapse for both ER+(R1)
and ER+(R2) patients.
The relationship between expression of c-erbB-2 mRNA
and disease-free survival of 21 ER- patients is given in
Figure 4. Eight out of nine observed relapses were associated
with c-erbB-2 mRNA overexpression. This indicated that, for
ER- patients, relapses were strongly correlated with c-erbB-2
gene overexpression. It is interesting to note that ER-
patients expressing normal or moderate levels of c-erbB-2
mRNA constitute a group having a relative low risk of
relapse, comparable to the low risk of relapse of ER+(RI)
patients. In other words, ER+(R2) is a better predictor of
relapse than ER negativity for patients expressing relatively
low levels of c-erbB-2 mRNA (<20 pg).
Table IV c-erbB-2 mRNA expression versus ER-/ER+(R) status:
relative risk ofrelapse analysed by thelogrank test for89 breastcancer
patients
c-erbB-2 ER-/ER+(R) Number Expected Observed
mRNAa status ofcases relapses relapses Obs/Exp
<20 ER- 12 2.6 1 0.4
ER+(R1) 33 9.5 2 0.2
ER+(R2) 24 5.8 6 1
>20 ER- 9 1.1 8 7.3
ER+(R1) 7 2.1 2 1
ER+(R2) 4 0.9 3 3.4
'Expressed inpgofspecificmRNAper4ygtotal RNA. bAsdefined in
the legend to Table III. P< 10-5.
,< ,_, ....... ,,{ ., .: .............., .w ..........................
........... k * s . p E! ...............
*: .N. : 1 fi;< (;
M c ;f;t ; ; .> !':i,! -'j ..v
~~~~~~~~~~~~~~~~~~~~.;....,}{Af SRi W*%if ;s6leZs ....Fs¢~~~~!~. z:--r-s4- ri.55 1 i.9.-f'.T I4 5.1',}q-'
4 4~~ ~ ~ ~ ~ ~~~44
5 .- . &_ ** ER+IR7 .-''. ev
-. .E flFS-w -_
Figure 3 Disease-free survival curves in ER-positive breast
cancer patients stratified by ER'(R) groups. Top and bottom
panels correspond to patients having less and more than 20 pg of
c-erbB-2 mRNA per 4 fig of total RNA extracted from tumours,
respectively.
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Figure 4 Disease-free survival curves in ER-negative breast
cancer patients stratified by c-erbB-2 mRNA levels. c-erbB-2
mRNA was expressed in pg per 4 ig of total RNA extracted
from tumours. Two events were noted at 3 months in the group
of patients overexpressing c-erbB-2 mRNA.
Discussion
We recently defined a new early prognostic factor, the
ER+(R) status, which permits one to discriminate among the
ER positive patients, a group presenting a high risk of early
relapse (May et al., 1989). This group was referred to as
ER+(R2) in contrast to ER+(R1) which corresponded to a
group of ER positive patients having a lower risk of early
relapse.
In the present study we performed a multivariate analysis
to evaluate the prognostic significance of ER+(R) status in
relation to c-erbB-2 mRNA overexpression and other classi-
cal parameters used in breast cancer prognosis.
Levels of c-erbB-2 mRNA were evaluated by Northern
blotting in 89 primary human breast carcinomas from non-
treated patients for whom comprehensive clinical follow-up
data was available. High expression of c-erbB-2 mRNA is
significantly correlated with ER negativity, inflammatory
tumours and with lymph node involvement, all of which are
indicators of poor prognosis. While conflicting results con-
cerning the correlation between c-erbB-2 gene amplification
and/or overexpression and other classical prognostic factors
have been reported in the literature (see Table I), our results
are in agreement with those obtained by Guerin et al. (1989)
from an independent population of patients from the same
Cancer Institute.
Concerning the prognostic value of ER+(R) status, we
found no correlation between this factor and c-erbB-2
mRNA. We previously showed the absence of a significant
correlation between ER+(R) status and histological grade of
the tumour or lymph node involvement. Results presented
here extend the assessment of ER+(R) status as an independ-
ent prognostic factor to c-erbB-2 gene expression.
In a multivariate survival analysis, with a median follow-
up of 30 months, we found that c-erbB-2 mRNA overexpres-
sion was a highly significant short-term predictor of relapse
(P = 0.02). These results agree with those published by
Varley et al. (1987), Slamon et al. (1987, 1989), Wright et al.
(1989) and Tandon et al. (1989), although the medium
follow-up available for our studies was shorter than that for
these authors.
It is interesting to note that the level of c-erbB-2 tran-
scripts significant for the prediction of short-term relapse
corresponds to at least 10-fold the MCF-7 level considered as
normal. This observation corroborates published data show-
ing that gene amplification correlated with the highest levels
of overexpression and that the group with the highest copy
number showed the greatest difference in prognosis when
compared with the single copy group (Slamon et al., 1987,
1989). Therefore, analysis ofc-erbB-2 mRNA expression may
be a sensitive assay provided that the cut-off value is care-
fully determined.
We found no correlation between lymph node involvement
and early relapse. This observation is not inconsistent with
previous data giving a significant value of lymph node
involvement with longer available follow-up (Contesso et al.,
1975). Considering this observation with the fact that c-erbB-
2 overexpression was significantly correlated with lymph
node involvement and disease free survival, it is tempting to
suggest that c-erbB-2 overexpression is an earlier event than
lymph node involvement towards the development or pro-
gression of breast cancer. This assumption is in agreement
with the fact that an overexpression of c-erbB-2 may be
detected as early as stage I and II of mammary tumours
(Lacroix et al., 1989).
On the other hand, multivariate analysis showed that the
two other worst factors for predicting a poor short-term
prognosis were ER negativity and ER+(R2). Previously, we
evaluated the prognostic significance of ER+(R) status from
a population restricted to ER' patients. Here we extended
this idea and showed that ER+(R) status is a significant
predictor of disease-free survival for the whole population
including the ER- patients and inflammatory tumours. In a
multivariate analysis including clinical tumour type, c-erbB-2
expression and ER-/ER+(R) status, inflammatory tumours
are not longer significant whereas ER- and ER+(R2) are.
The results of the log rank test (Table IV) and the DFS
curves (Figures 2 and 3) showed that patients having a
particularly poor prognosis were those with tumours contain-
ing high-levels of c-erbB-2 mRNA and either ER- or ER'
(R2). An unexpected observation was that ER- patients with
no overexpression of c-erbB-2 had a relatively low risk of
early relapse.
In conclusion, data presented here and elsewhere (May et
al., 1989) strongly suggest that both populations of ER' and
ER- patients could be divided into two groups presenting
either a low or high risk of early relapse. We found that
among ER' patients, ER+(R2) patients had a higher risk of
early relapse especially when c-erbB-2 was overexpressed. On
the contrary, we observed that ER- patients with low or
moderate amounts of c-erbB-2 had a good short-term prog-
nosis.
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